Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12677569 | 0.87 | MDM4 (0.49) | CASP3MDM4TP53KMT2A | |
| SCHEMBL30261589 | 0.87 | CTSB (0.49) | CASP3CTSBCTSKPIN1 | |
| SCHEMBL30945916 | 0.85 | MDM4 (0.46) | CASP3MDM4TP53TLR2 | |
| SCHEMBL30887592 | 0.84 | CASP3 (0.49) | CASP3CTSBPIN1CTSLCTSS | |
| SCHEMBL31546599 | 0.83 | POLB (0.51) | CASP3PIN1KMT2A | |
| SCHEMBL14019298 | 0.83 | POLB (0.51) | CASP3PIN1KMT2A | |
| Hydrochloric Acid SCHEMBL30261623 | 0.83 | CASP3 (0.45) | CASP3CTSBCTSKMDM4TP53 | |
| SCHEMBL29462654 | 0.82 | CASP3 (0.55) | CASP3CTSBPIN1MDM4TP53 | |
| SCHEMBL28557417 | 0.82 | MDM4 (0.45) | CASP3MDM4TP53KMT2A | |
| SCHEMBL28557416 | 0.82 | MDM4 (0.45) | CASP3MDM4TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | CASP3 2701/4885CTSB 236/4885CTSK 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.